IGF1R and sarcoma: To date, we have completed the following sarcoma study: “A phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor for the treatment of patients with recurrent or refractory Ewing's sarcoma.” In this study, using our response assessment system, we delineated and measured target lesions in 101 patients with sarcoma (303 scan time points).